Journal Mobile Options
Table of Contents
Vol. 7, No. 1-3, 2010
Issue release date: April 2010

Effects of Dopamine Agonists on Neuropsychiatric Symptoms of Parkinson’s Disease

Rektorová I.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The efficacy of dopamine (DA) agonists in the treatment of motor symptoms of Parkinson’s disease (PD) has been clearly demonstrated. It has also been documented that DA agonists may have both a positive and a negative impact on neuropsychiatric symptoms in PD patients. This paper will focus on the effects of DA agonists on depressive and cognitive symptoms of PD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Goetz CG, Poewe W, Rascol O, Sampaio C: Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disord 2005;20:523–539.
  2. Chaudhuri KR, Healy DG, Schapira AHV: Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006;5:235–245.
  3. Burn DJ: Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease. Mov Disord 2002;17:445–454.
  4. Mega MS, Cummings JL: Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994;6:358–370.
  5. Jellinger KA: The pathology of Parkinson’s disease. Adv Neurol 2001;86:55–72.
  6. Pillon B, Dubois B, Cusimano G, Bonnet AM, Lhemitte F, Agid Y: Does cognitive impairment in Parkinson’s disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 1989;52:201–206.
  7. Emre M, Aarsland D, Brown R, et al: Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007;22:1689–1707.
  8. Rektorova I, Srovnalova H, Kubikova R, Prasek J: Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson’s disease. Mov Disord 2008;23:1580–1587.
  9. Remy P, Samson Y: The role of dopamine in cognition: evidence from functional imaging studies. Curr Opin Neurol 2003;16(suppl 2):S37–S41.
  10. Cheesman AL, Barker RA, Lewis SJ, Robbins TW, Owen AM, Brooks DJ: Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2005;76:1204–1210.
  11. Weintraub D, Newberg AB, Cary MS, et al: Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med 2005;46:227–232.
  12. Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M: Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson’s disease. Eur J Neurosci 2007;25:3132–3136.
  13. Rektorova I, Rektor I, Bares M, et al: Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multi-centre prospective randomized study. Eur J Neurol 2003;10:399–406.
  14. Rektorova I, Balaz M, Svatova J, et al: Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 2008;31:261–266.
  15. Rektorová I, Rektor I, Bares M, et al: Cognitive performance in people with Parkinson’s disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol 2005;12:9–15.
  16. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H: Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005;17:214–220.
  17. Barone P, Scarzella L, Marconi R, et al: Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease. A national multicenter parallel-group randomized study. J Neurol 2006;253:555–561.

    External Resources

  18. Pahwa R, Stacy MA, Factor SA, et al: Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson’s disease. Neurology 2007;68:1108–1115.
  19. Kulisevsky J, García-Sánchez C, Berthier ML, et al: Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000;15:613–626.
  20. Cools R: Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev 2006;30:1–23.
  21. Nieoullon A: Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53–83.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00